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Abstract Effector caspases-3, -6 and -7 are responsible for
producing the morphological features associated with apoptosis,
such as DNA fragmentation. The present study demonstrates
that a member of a novel series of pyrrolo-1,5-benzoxazepines,
PBOX-6, induces apoptosis in MCF-7 cells, which lack caspase-
3. Apoptosis was accompanied by DNA fragmentation and the
activation of caspase-7, but not caspases-3 and -6. Inhibition of
caspase-7 activity reduced the extent of apoptosis induced,
indicating that activation of caspase-7 is involved in the
mechanism by which PBOX-6 induces apoptosis in MCF-7 cells.
This study suggests that caspase-3 is not necessarily essential for
DNA fragmentation and the morphological changes associated
with apoptosis. ß 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis is a cell suicide mechanism invoked in disparate
situations to remove redundant, damaged, or infected cells.
An essential component of the apoptotic machinery, the cas-
pase family, consists of a group of intracellular cysteine pro-
teases with at least 14 members [1]. They can be divided into
initiator or upstream caspases (caspases-2, -8, -9, and -10),
which go on to activate the downstream or e¡ector caspases
(caspases-3, -6 and -7). Cleavage of a select group of sub-
strates by e¡ector caspases is responsible for dismantling of
essential cell components, which results in morphological and
biochemical changes that characterise apoptotic cell death:
cytoskeletal rearrangement, cell membrane blebbing, nuclear
condensation and DNA fragmentation [2]. For example, in in
vitro studies caspase-3 cleaves ICAD (inhibitor of caspase-
activated DNase), promoting release of active CAD (cas-
pase-activated DNase), which then cleaves DNA and pro-
motes chromatin condensation [3,4].
Previous work has demonstrated that MCF-7 breast carci-
noma cells, which lack caspase-3 owing to a functional dele-
tion in the CASP-3 gene, can be killed by apoptotic stimuli,
such as tumour necrosis factor (TNF) and staurosporine,
without DNA fragmentation and many of the other hallmarks
of apoptosis [5]. These results indicated that caspase-3 was
likely to be essential for such hallmarks of apoptotic cell
death. In contrast to this, a recent report has revealed that
release of mitochondrial endonuclease G results in DNA frag-
mentation in murine embryonic ¢broblast cells following UV
irradiation, which occurs independently of caspase activation
[6]. In addition, apoptosis-inducing factor has been shown to
induce apoptosis in a caspase-independent manner [7]. In a
recent study we have shown that some members of a series of
novel pyrrolo-1,5-benzoxazepines (PBOXs) induce apoptosis
as shown by cell shrinkage, chromatin condensation, and
DNA fragmentation in three human cell lines, HL-60 promye-
locytic, Jurkat T lymphoma and Hut-78 lymphoma cells [8].
This indicated the potential of these compounds for use as
anti-cancer drugs and prompted us to examine both the e¡ect
of these compounds on other cancerous cell lines and the
mechanism by which these novel compounds induce apopto-
sis. In the present study we determined whether a potent
member of this series, PBOX-6, could induce apoptosis in
MCF-7 cells, which of the remaining e¡ector caspases (-6
and -7) were activated in response to PBOX-6 treatment
and whether apoptotic cell death in this case was accompanied
by the usual morphological features such as DNA fragmenta-
tion. This study enabled us to determine whether caspase-3 is
really an absolute requirement for DNA fragmentation asso-
ciated with apoptosis in intact cells or whether another e¡ec-
tor caspase such as caspase-6 or -7 may mediate this apoptotic
hallmark in caspase-3-de¢cient MCF-7 cells.
2. Materials and methods
2.1. Cell culture and induction of apoptosis
MCF-7 breast carcinoma cells were obtained from the European
Collection of Animal Cell Culture (Salisbury, UK) and were grown in
minimum essential medium supplemented with 1% non-essential ami-
no acids, 10% foetal calf serum, gentamicin (0.1 mg/ml), and L-gluta-
mate (¢nal concentration 2 mM), all obtained from Sigma (Poole,
Dorset, UK). The pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)-
oxy]-6-(2-naphthyl)pyrrolo-[2,1-d][1,5]-benzoxazepine (PBOX-6) was
synthesised as described previously [8]. Cells were seeded at a density
of 3U105 cells/ml and following treatment with the PBOX-6 or the
caspase-7 inhibitor, DEVD-cmk (Calbiochem-Novabiochem, Notting-
ham, UK), an aliquot (100 Wl) was cytocentrifuged onto glass slides
precoated with poly-L-lysine. They were then stained with the Rapi-
Di¡ kit (Diagnostic Developments, Burscough, Lancashire, UK)
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under conditions described by the manufacturer. The degree of apo-
ptosis and necrosis was determined by counting approximately 300
cells under a light microscope. At least three ¢elds of view per slide,
with an average of approximately 100 cells per ¢eld, were counted and
the percent apoptosis and necrosis were determined. TUNEL staining,
characteristic of DNA fragmentation, was performed as described
previously [9]. Cells were ¢xed in 4% paraformaldehyde, permeabilised
in 0.1% Triton X-100 solution and labelled using terminal transferase
and horseradish peroxidase (Boehringer Mannheim). Colorimetric de-
tection was performed using diaminobenzidine.
2.2. Caspase assay
Cells (5U106 cells) were harvested by trypsinisation, centrifugation,
washing in ice-cold phosphate-bu¡ered saline and the pellets resus-
pended in 200 Wl of harvesting bu¡er (20 mM HEPES, pH 7.5, 10%
(w/v) sucrose, 0.1% (w/v) CHAPS, 2 mM dithiothreitol, 0.1% (v/v)
Nonidet NP40, 1 mM sodium EDTA and 1 mM phenylmethylsul-
fonyl £uoride) supplemented with protease inhibitors (1 Wg/ml pepsta-
tin A and 1 Wg/ml leupeptin). Following incubation on ice for 15 min,
samples were centrifuged at 20 000Ug for 20 min and the resulting
supernatants used to measure caspase-6 or -7 activity. This enzyme
activity was determined by a £uorometric assay using either the sub-
strate Ac-DEID-AMC or Ac-DEVD-AMC (Alexis, Nottingham,
UK), which is cleaved by caspase-6 or -7, respectively, to release the
£uorescent leaving group, amino-4-methyl coumarin (AMC). Enzyme
extracts (50 Wg) were incubated with 100 mM HEPES, pH 7.5, con-
taining 10% (w/v) sucrose, 0.1% (w/v) CHAPS, 10 mM dithiothreitol
and 20 WM substrate in a total reaction volume of 3 ml. Following
incubation for 60 min at 25‡C, £uorescence was monitored continu-
ously using a spectro£uorimeter (excitation wavelength 380 nm, emis-
sion wavelength 460 nm). The amount of AMC released was deter-
mined by comparison with a standard curve generated with known
amounts of AMC. Western blotting to measure expression of pro-
caspase-3 in MCF-7 cell extracts was performed as previously de-
scribed [7] using an anti-pro-caspase-3 antibody (Pharmingen, San
Diego, CA, USA).
2.3. Fluorescence-activated cell sorting (FACS) analysis
FACS analysis was performed as described previously [10] with a
FACScalibur £ow cytometer (Becton Dickinson). Analysis of data
was performed using the computer programme Cell Quest.
3. Results and discussion
3.1. DNA fragmentation can be induced in MCF-7 cells during
PBOX-6-mediated apoptosis
MCF-7 cells were shown to undergo apoptosis in response
to PBOX-6 treatment in a dose- and time-dependent manner
(Fig. 1A,B). This induction of apoptosis was accompanied by
many of the typical morphological features associated with
apoptotic cell death, including cell shrinkage, chromatin con-
densation and nuclear fragmentation as observed by light mi-
croscopy of cytospin preparations (Fig. 2A,B). In contrast to
this result other reports have shown that MCF-7 cells treated
with various apoptotic stimuli (e.g. transforming growth fac-
tor-L1, etoposide and TNF) undergo cell death in the absence
of DNA fragmentation [5,11]. In agreement with these re-
ports, we have shown that TNF/cycloheximide (Chx) treat-
ment of MCF-7 cells resulted in cell death but that nuclear
fragmentation was not observed (Fig. 2C). TUNEL staining
(Fig. 3A,B) of PBOX-6-treated MCF-7 cells con¢rmed that
apoptotic cell death in response to this death stimuli was
accompanied by DNA fragmentation. In addition cell cycle
analysis with propidium iodide-stained cells (Fig. 3C) con-
¢rmed these results, because PBOX-6 induced the appearance
of a sub-G1 apoptotic peak (22% of cells in PBOX-6-treated
cells compared to less than 3% in control cells) characteristic
of DNA fragmentation. These results indicate that only some
death stimuli (e.g. TNF), that induce apoptosis in MCF-7
cells, do so without the accompaniment of DNA fragmenta-
tion.
3.2. Activation of caspase-7 accompanies the induction of
apoptosis by PBOX-6 in MCF-7 cells
It has been widely reported that MCF-7 cells do not express
detectable levels of caspase-3, a result that we have con¢rmed
by Western blotting (results not shown). Caspase-3 has been
reported to initiate DNA fragmentation by proteolytically in-
activating ICAD, which releases the active endonuclease
CAD. This endonuclease then cleaves DNA. It has thus
been suggested that caspase-3 is essential for DNA fragmen-
tation during apoptosis [5]. In contrast to this, the results
Fig. 1. PBOX-6 induces apoptosis in MCF-7 cells in a dose- and
time-dependent manner. MCF-7 cells were seeded at a density of
2U105 cells/ml and were treated with (A) either a range (0^50 WM)
of concentrations of PBOX-6 for 16 h or (B) one concentration of
PBOX-6 (25 WM) for a period of 4, 8, 16, 24, 48 and 72 h. The per-
centage of apoptosis was determined by cytospinning and staining
the cells with the RapiDi¡ kit. Values represent the means þ S.E.M.
for three separate experiments.
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presented here suggest that another e¡ector caspase may take
over the role of caspase-3 in mediating DNA fragmentation in
caspase-3-de¢cient MCF-7 cells. We thus examined whether
the other e¡ector caspases-6 and/or -7 become activated in
MCF-7 cells in response to PBOX-6 treatment. Like cas-
pase-3, caspase-7 cleaves a DEVD-based peptide substrate,
whereas caspase-6 cleaves a DEID-based peptide substrate
[1]. Cytosolic extracts from MCF-7 cells treated with
PBOX-6 were incubated with either the £uorogenic caspase-
6 substrate DEID-AMC or the caspase-7 substrate DEVD-
AMC. HL-60 cells treated with etoposide (50 WM for 6 h)
were used as a positive control for caspase-6 activation. As
shown in Fig. 4A, treatment of MCF-7 cells with PBOX-6 did
not cause activation of caspase-6 but did result in caspase-7
activation (Fig. 4B).
3.3. Caspase-7 activity is involved in PBOX-6-mediated
apoptosis
Caspases are speci¢cally inhibited in vitro and in vivo by
cell permeable tetrapeptides designed to mimic cleavage sites
of their respective substrates [12]. Pretreatment of MCF-7
cells with the caspase-7 inhibitor, z-DEVD-cmk, followed by
treatment for a further 24 h with PBOX-6 signi¢cantly re-
duced both the activity of caspase-7 (Fig. 4B) and the appear-
ance of the morphological signs of apoptosis (Fig. 4C). Inhi-
bition of caspase-7 activity correlated directly with the level of
protection observed against apoptosis. Pretreatment of MCF-
7 cells for 1 h with the general caspase inhibitor, z-VAD-fmk
(200 WM), inhibited the appearance of the morphological signs
of apoptosis to the same extent as that shown with z-DEVD-
fmk, however, no protective e¡ect against apoptosis was ob-
served when cells were treated with the caspase-1-like inhib-
itor, YVAD-fmk (results not shown). This would suggest that
caspase-7 is involved in the mechanism by which PBOX-6
induces apoptosis in MCF-7 cells.
3.4. Caspase-7 may be responsible for DNA fragmentation in
apoptotic MCF-7 cells
Because neither caspase-3 (due to its lack of expression in
these cells) nor caspase-6 becomes activated in MCF-7 cells in
Fig. 2. Morphological assessment of chromatin condensation and
nuclear fragmentation in MCF-7 cells undergoing apoptosis in re-
sponse to treatment with PBOX-6. Microscopic analysis of MCF-7
cells was performed on cytospin samples which were ¢xed in metha-
nol. The nucleus was stained pink with eosin-Y and the cytoplasm
was stained blue with methylene blue. Vehicle (1% ethanol)-treated
cells (A) are characterised by a continuous plasma membrane and
an intact nucleus. PBOX-6-treated cells (B) display the morphologi-
cal features of apoptosis that include chromatin condensation and
nuclear fragmentation. TNF/Chx-treated cells (C) display a lack of
nuclear fragmentation.
Fig. 3. Con¢rmation of DNA fragmentation in MCF-7 cells, in re-
sponse to PBOX-6 treatment, by TUNEL staining and FACS analy-
sis. TUNEL staining of vehicle- (A) or PBOX-6-treated (48 h)
MCF-7 cells (B). C: Changes in cell cycle phase distribution follow-
ing PBOX-6 treatment of MCF cells. The cell cycle phases G1, S
and G2/M as well as the sub-G1 apoptotic peak are indicated.
FACS analysis was performed with propidium iodide-stained cells
as described in Section 2.
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response to PBOX-6 treatment this would suggest that the
other remaining e¡ector caspase, caspase-7, which becomes
activated, may be responsible for the DNA fragmentation
exhibited by MCF-7 cells treated with PBOX-6. This sugges-
tion is supported by a recent report which demonstrated that
in an in vitro CAD assay, of all the proteinases suggested to
participate in apoptotic DNA fragmentation, only caspase-3
and caspase-7 induced DNA fragmentation by inactivating
ICAD [1]. These workers also showed that in vitro, however,
caspase-3 inactivated ICAD and promoted DNA fragmenta-
tion more e¡ectively than caspase-7. In agreement with this
report, we suggest that although caspase-3 may be the pri-
mary regulator of apoptotic DNA fragmentation via proteol-
ysis of ICAD, caspase-7 may mediate this apoptotic hallmark
in response to certain death stimuli such as PBOX-6, in cas-
pase-3-de¢cient cells. As we were unable to completely inhibit
apoptosis using the general caspase inhibitor, z-VAD-fmk, or
the caspase-7 inhibitor, z-DEVD-fmk, we cannot exclude the
possibility that in addition to caspase-7, non-caspase pro-
teases such as cathepsins, or endonuclease G, may also par-
ticipate in apoptosis induced by PBOX-6. We also show in the
present study that apoptosis induction in MCF-7 cells in re-
sponse to TNF/Chx treatment does not result in caspase-7
Fig. 4. PBOX-6 induces apoptosis in MCF-7 cells through activa-
tion of caspase-7. A: Cytosolic extracts (50 Wg of protein) prepared
from either HL-60 cells treated with etoposide (50 WM) for 6 h or
from MCF-7 cells treated with PBOX-6 (25 WM) for 24 h were in-
cubated with DEID-AMC to assess caspase-6 activation. The
amount of £uorochrome released was determined by comparison to
an AMC standard curve. B and C: MCF-7 cells were treated with
PBOX-6 (25 WM) for 24 h, in the absence or presence of the inhibi-
tor DEVD-cmk (200 WM). Cytosolic extracts (50 Wg of protein)
were prepared and were incubated with DEVD-AMC to assess cas-
pase-7 activation (B). The percentage of apoptosis was determined
by cytospinning and staining the cells with the RapiDi¡ kit (C).
Values represent the means þ S.E.M. of three separate experiments.
C
Fig. 5. Lack of activation of caspase-7 in MCF-7 cells in response
to treatment with TNF/Chx. Cytosolic extracts (50 Wg of protein)
prepared from MCF-7 cells treated with either TNF/Chx for 20 h
or PBOX-6 for 24 h were incubated with DEVD-AMC to assess
caspase-7 activation. The amount of £uorochrome released was de-
termined by comparison to an AMC standard curve. Values repre-
sent the means þ S.E.M. of four separate experiments.
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activation (Fig. 5). This may explain why DNA fragmentation
does not occur in MCF-7 cells in response to TNF/Chx.
In this study we report the detection of caspase-7-like DEV-
Dase activity in extracts from MCF-7 apoptotic cells. These
results are in agreement with Germain et al. [13] who reported
that staurosporine treatment of MCF-7 cells resulted in cas-
pase-7 activation with concomitant cleavage of Parp. Apopto-
sis induced by PBOX-6 in MCF-7 cells was associated with
DNA fragmentation, as demonstrated by light microscopy,
TUNEL staining and propidium iodide staining with FACS
analysis. This is in contrast to the recent study showing that
apoptotic MCF-7 cells, despite caspase-7 activation, failed to
fragment DNA [1]. However the stimulus used to induce ap-
optosis in MCF-7 cells was not reported. Perhaps in that
particular instance caspase-7 activation did not reach the level
required to initiate DNA fragmentation.
In conclusion, induction of apoptosis in MCF-7 cells by a
novel pyrrolobenzoxazepine, PBOX-6, appears to be mediated
in part by activation of one of the e¡ector caspases, caspase-7.
Apoptosis is accompanied by DNA fragmentation, suggesting
that in these caspase-3-de¢cient cells, caspase-7 may mediate
this apoptotic hallmark. It would also suggest that caspase-3
is not necessarily essential for DNA fragmentation associated
with apoptosis.
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